Literature DB >> 29549134

Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.

Fayez Hanna1, Ajay Prakash2,3, Ebony Allan3, Alhossain A Khalafallah1,3,4,5.   

Abstract

A 70-year-old man presented with left loin pain without urinary symptoms. Initial investigations with CT showed enlarged para-aortic, mediastinal lymph nodes, right-side renal mass and enlarged prostate. A prostatic-specific antigen (PSA) was alarmingly high at 4750 μg/L (normal <4.0 μg/L). Further investigations included positron emission tomography (PET); both prostate-specific membrane antigen and 18-fluorodeoxyglucose as well as bone scan and bone marrow examination confirmed dual malignancies with B-cell non-Hodgkin's lymphoma (B-NHL) and wide spread metastatic prostatic adenocarcinoma (PA) to the skull, spine, pelvis, liver and lungs. The patient was treated with six cycles of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin(R-EPOCH) containing regimen for B-NHL and goserelin hormonal therapy for PA. Restaging with PET scans thereafter showed complete remission of NHL with disappearance of his metastatic PA and normalisation of PSA levels. R-EPOCH regimen and antiandrogen therapy resulted in a good outcome and remission of both malignancies. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  malignant and benign haematology; malignant disease and immunosuppression; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29549134      PMCID: PMC5878372          DOI: 10.1136/bcr-2017-223637

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.

Authors:  Javier A Laurini; Anamarija M Perry; Eugene Boilesen; Jacques Diebold; Kenneth A Maclennan; H Konrad Müller-Hermelink; Bharat N Nathwani; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

2.  Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.

Authors:  Zoran Persec; Jasminka Persec; Tomislav Sović; Zeljko Romic; Maja Bosnar Herak; Zlatko Hrgovic
Journal:  Onkologie       Date:  2010-02-22

3.  Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases.

Authors:  Peiguo G Chu; Qin Huang; Lawrence M Weiss
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

4.  Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Ken-Ichiro Shiga; Hirofumi Koga; Akito Yamaguchi; Seiji Naito; Masatoshi Eto
Journal:  BJU Int       Date:  2016-04-06       Impact factor: 5.588

5.  False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney.

Authors:  B Djavan; J H Keffer; K Molberg; C G Roehrborn
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

6.  Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project.

Authors:  Anamarija M Perry; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger
Journal:  Ann Hematol       Date:  2015-11-05       Impact factor: 3.673

Review 7.  Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature.

Authors:  Antonio Di Meglio; Pier Vitale Nuzzo; Francesco Ricci; Bruno Spina; Francesco Boccardo
Journal:  BMC Cancer       Date:  2014-08-26       Impact factor: 4.430

8.  Primary non-Hodgkin's lymphoma of the prostate with intractable hematuria: A case report and review of the literature.

Authors:  Shanbiao Hu; Yinhuai Wang; Luoyan Yang; Lu Yi; Yeqi Nian
Journal:  Oncol Lett       Date:  2014-12-24       Impact factor: 2.967

9.  Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.

Authors:  Nikolai Mühlberger; Kristijan Boskovic; Murray D Krahn; Karen E Bremner; Willi Oberaigner; Helmut Klocker; Wolfgang Horninger; Gaby Sroczynski; Uwe Siebert
Journal:  BMC Public Health       Date:  2017-06-26       Impact factor: 3.295

10.  Primary Extranodal Diffuse Large B-Cell Lymphoma of the Prostate: A Case Report.

Authors:  Daniel E Ezekwudo; Foluso Ogunleye; Bolanle Gbadamosi; LeAnn M Blankenship; Michael Kinoyan; Daniel Krauss; Mitchell Hollander; Kristle Haberichter; Ishmael Jaiyesimi
Journal:  Case Rep Oncol       Date:  2017-02-15
View more
  1 in total

1.  18F-Prostate-Specific Membrane Antigen and 18F-Fluorodeoxyglucose PET/CT Unmasked the Characteristics of Prostate Lymphoma: A Case Report and Literature Review.

Authors:  Fan Jiang; Junjie Fan; Hua Liang; XiaoYi Duan; Dalin He; Kaijie Wu
Journal:  Front Med (Lausanne)       Date:  2022-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.